These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16828002)

  • 21. [Hepatitis C: the recovery].
    Marcellin P
    Gastroenterol Clin Biol; 2009; 33(8-9):819-29. PubMed ID: 19541439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus.
    Torresi J; Johnson D; Wedemeyer H
    J Hepatol; 2011 Jun; 54(6):1273-85. PubMed ID: 21236312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fifteen years of investigations on hepatitis C virus in Poland].
    Juszczyk J
    Przegl Epidemiol; 2005; 59(2):373-84. PubMed ID: 16190544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence.
    Bizollon T; Ahmed SN; Radenne S; Chevallier M; Chevallier P; Parvaz P; Guichard S; Ducerf C; Baulieux J; Zoulim F; Trepo C
    Gut; 2003 Feb; 52(2):283-7. PubMed ID: 12524414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin.
    Jimenez-Sousa MA; Almansa R; de la Fuente C; Caro-Paton A; Ruiz L; Sanchez-Antolín G; Gonzalez JM; Aller R; Alcaide N; Largo P; Resino S; de Lejarazu RO; Bermejo-Martin JF
    Eur Cytokine Netw; 2010 Jun; 21(2):84-91. PubMed ID: 20483710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients.
    Terrier B; Saadoun D; Sène D; Sellam J; Pérard L; Coppéré B; Karras A; Blanc F; Buchler M; Plaisier E; Ghillani P; Rosenzwajg M; Cacoub P
    Arthritis Rheum; 2009 Aug; 60(8):2531-40. PubMed ID: 19644879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C therapy: other players in the game.
    Ahn J; Flamm SL
    Clin Liver Dis; 2011 Aug; 15(3):641-56. PubMed ID: 21867942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C.
    el-Sayed AM; Sharara AI
    J Med Liban; 2001; 49(2):71-7. PubMed ID: 11910970
    [No Abstract]   [Full Text] [Related]  

  • 30. Strategies for hepatitis C therapeutic intervention: now and next.
    Tan SL; He Y; Huang Y; Gale M
    Curr Opin Pharmacol; 2004 Oct; 4(5):465-70. PubMed ID: 15351350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Novel methods of hepatitis C treatment and prevention].
    Chmielewska AM; Rychłowska M; Król E; Solarz K; Bieńkowska-Szewczyk K
    Postepy Hig Med Dosw (Online); 2015 Aug; 69():946-63. PubMed ID: 26400881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hepatitis B and C: From molecular virology to new antiviral therapies (part 1)].
    Thimme R; Heim M; Baumert TF; Nassal M; Moradpour D
    Dtsch Med Wochenschr; 2014 Mar; 139(13):655-9. PubMed ID: 24648178
    [No Abstract]   [Full Text] [Related]  

  • 33. Containing "The Great Houdini" of viruses: combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C.
    Ahlén G; Frelin L; Brenndörfer ED; Brass A; Weiland O; Chen M; Sällberg M
    Drug Resist Updat; 2013; 16(3-5):60-7. PubMed ID: 23911647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene therapies for hepatitis C virus.
    Verstegen MM; Pan Q; van der Laan LJ
    Adv Exp Med Biol; 2015; 848():1-29. PubMed ID: 25757613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New treatments to reach functional cure: Rationale and challenges for emerging immune-based therapies.
    Gehring AJ
    Best Pract Res Clin Gastroenterol; 2017 Jun; 31(3):337-345. PubMed ID: 28774416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current and future concepts in hepatitis C therapy.
    Pawlotsky JM
    Semin Liver Dis; 2005 Feb; 25(1):72-83. PubMed ID: 15731999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.
    Durantel D; Zoulim F
    J Hepatol; 2016 Apr; 64(1 Suppl):S117-S131. PubMed ID: 27084032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current issues in the management of paediatric viral hepatitis.
    Yeung LT; Roberts EA
    Liver Int; 2010 Jan; 30(1):5-18. PubMed ID: 19840256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
    Pár A; Tornai I; Szalay F
    Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
    Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P
    Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.